Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Background Recent guidelines recommend consideration of the use of oral edoxaban or
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …

Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients
with cancer. Over the past 2 decades, enormous advances have been made in the …